EvaluatePharma World Preview 2015, Outlook to 2020

Worldwide Rx Sales Forecast to Grow 5% p.a. to 2020. Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Key highlights

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.

EvaluatePharma World Preview 2017, Outlook to 2022

Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years

The new edition of our annual report,  EvaluatePharma World Preview 2017, Outlook to 2022 discusses the impact that increased scrutiny around the pricing of medicines is starting to have on drug sales growth.

Despite consensus forecasts for worldwide drug sales hitting $1.06trn in 2022, this is down from the $1.12trn analysts forecast for the same period last year. The fall also represents the first time in 10 years of Evaluate analysis that total drug sales have failed to beat previous year forecasts. 

This report brings together many of our analyses to provide a top level insight, from the world's financial markets, into the expected performance of the industry between now and 2022.

Key Highlights

  • Worldwide prescription drug sales forecasted to grow at a robust 6.5% (CAGR) through 2022 to reach $1.06trn

  • 32% of the 2022 increase in sales to come from orphan drugs (+$95bn)

  • Sales at risk worth $194bn potentially signal a second patent cliff era with the advent of biosimilars

  • Novartis, Pfizer and Roche to compete head to head for the crown of worldwide RX sales in 2022, but Novartis seems to have a slight edge

  • Celgene (+15%) and Shire (+10%) expected to record the fastest sales growth(CAGR) by 2022 although growth estimates have been revised downward in the last 12 months

View EvaluatePharma World Preview 2017, Outlook to 2022 Executive Summary

Download